Forte Biosciences, Inc. 8-K

What Happened

• Forte Biosciences, Inc. (FBRX) filed an 8-K on April 9, 2026 disclosing an underwriting agreement dated April 8, 2026 for a public offering of 5,709,936 shares of common stock at $26.27 per share. The underwriter representative is Guggenheim Securities, LLC. The company granted the underwriters a 30‑day option to purchase up to an additional 856,490 shares. Gross proceeds are expected to be approximately $150 million (before fees), with estimated net proceeds of about $141 million (or about $162 million if the option is fully exercised). The offering is expected to close on or about April 10, 2026, subject to customary closing conditions.

Key Details

• Shares offered: 5,709,936 common shares at $26.27 per share.
• Underwriter option: 856,490 additional shares exercisable for 30 days.
• Proceeds: ~ $150M gross; estimated net proceeds ~$141M (or ~$162M if option exercised).
• Underwriter: Guggenheim Securities, LLC (representative). Offering made under the company’s effective Form S-3 registration statement.
• Additional disclosure: argenx BV made a strategic investment as part of the offering; press release and legal opinion (Wilson Sonsini Goodrich & Rosati, P.C.) are filed as exhibits.

Why It Matters

• The offering, if completed, will raise substantial cash for Forte (estimated net ~$141M), which can affect the company’s cash runway and funding for operations or development programs.
• It will also increase the number of shares outstanding and therefore dilute existing shareholders to a degree proportional to the new shares issued.
• The participation of argenx BV as a strategic investor may be viewed as validation by an industry peer, as disclosed in the filing.
• Completion is subject to customary closing conditions and market factors; the filing includes standard forward‑looking statement cautions.